

ADVANCED COURSE PROGRAMME

NTRK Gene Fusion: A New Target in Precision Treatment of Cancer

**ESMO VIRTUAL
ADVANCED COURSE**

**VIRTUAL
5-6 DECEMBER 2022**

Chairs:

Herbert H. F. Loong, Hong Kong
Andrea Sartore-Bianchi, Italy
Hongcheng Zhu, China

ESMO VIRTUAL ADVANCED COURSE PROGRAMME

NTRK GENE FUSION: A NEW TARGET IN PRECISION TREATMENT OF CANCER

5-6 December 2022

CO-CHAIRS: Herbert H. F. Loong, Hong Kong
Andrea Sartore-Bianchi, Italy
Hongcheng Zhu, China

SPEAKERS: Lisa Licitra, Italy
Yongmei Liu, China
Fernando Lopez-Rios, Spain
Shun Lu, China
Caterina Marchiò, Italy
Changsong Qi, China
Silvia Stacchiotti, Italy
Vivek Subbiah, United States
Aaron Tan, Singapore
Jian Wang, China
Stephen Yip, Canada
Yizhuo Zhang, China

LEARNING OBJECTIVES

- Acquire knowledge of the TRK family members and their roles in ontogenesis
- Understand the mechanisms of gene fusion and the different fusion partners involved
- Learn how TRK receptors are structured and how their activation impacts signal transduction
- Review the epidemiology of NTRK gene fusion in human tumours
- Understand the methodology to identify NTRK gene fusion and the challenges of testing
- Update knowledge on the present outcome obtained with NTRK inhibitors, their toxicities and clinical management

ACCREDITATION

The programme of this event has been accredited with **6 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano, Switzerland
Email: courses@esmo.org
www.esmo.org



All timings are to be considered GMT+ 8 (Singapore local time)

Monday, 5 December 2022

15:00-15:05 5'	Welcome and introduction Herbert H. F. Loong, HK Andrea Sartore-Bianchi, IT Hongcheng Zhu, CN
15:05-15:35 20'	Session 1 Advances in NTRK-fused tumours classification and diagnosis Stephen Yip, CA
10'	Discussion
15:35-16:05 20'	Session 2 The clinical and pathological spectrum of NTRK-rearranged mesenchymal tumours Jian Wang, CN
10'	Discussion
16:05-16:35 20'	Session 3 Challenges in molecular and pathological diagnosis of NTRK fusions in big killer cancers Fernando Lopez-Rios, ES
10'	Discussion
16:35-16:45	<i>Break</i>
16:45-17:35 20'	Session 4 Overview of Efficacy of NTRK Inhibitors: Global Perspective Vivek Subbiah, US
20'	Overview of Efficacy of NTRK Inhibitors: Asian/Chinese Perspective Shun Lu, CN
10'	Discussion
17:35-18:05 20'	Session 5 Acquired resistance to NTRK inhibitors and development of inhibitors targeting resistance mutations Aaron Tan, SG
10'	Discussion
18:05-18:35 20'	Session 6 Looking into the Future: Is there room for combinational approaches to NTRK inhibition? Herbert H. F. Loong, HK
10'	Discussion

Tuesday, 6 December 2022

15:00-15:30 20'	Session 7 Clinical data on NTRK-fused tumours: Sarcoma Silvia Stacchiotti, IT
10'	Discussion
15:30-16:00 20'	Session 8 Clinical data on NTRK-fused tumours: Lung Cancer / Thoracic Malignancies Yongmei Liu, CN
10'	Discussion
16:00-16:30 20'	Session 9 Clinical data on NTRK-fused tumours: GI Changsong Qi, CN
10'	Discussion
16:30-16:40	<i>Break</i>
16:40-17:10 20'	Session 10 Clinical data on NTRK-fused tumours: Paediatric Yizhuo Zhang, CN
10'	Discussion
17:10-17:40 20'	Session 11 Clinical data on NTRK-fused tumours: H & N Lisa Licitra, IT
10'	Discussion
17:40-18:20	Workshop session
Workshop 1 40'	Workshop for Medical Oncologists & Pathologist Caterina Marchiò, IT Silvia Stacchiotti, IT
	Structure: <ul style="list-style-type: none">• Presentation of 1/2 clinical cases by speakers (1/2 different NTRK tumours type)• Technical aspects of NTRK diagnosis technics (theoretical aspects, methods)• Discussion & questions
18:20-18:30 10'	Conclusion and farewell Herbert H. F. Loong, HK Andrea Sartore-Bianchi, IT Hongcheng Zhu, CN